UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
|
x
|
Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
For the quarterly period ended September 30, 2008
|
¨
|
Transition report under Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Commission file number: 33-55254-36
E Med Future, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Nevada
|
|
87-0485314
|
|
(State of incorporation)
|
|
(I.R.S. Employer Identification No.)
|
34 South Clay Street, Millersburg, Ohio 44654
(Address of principal executive offices)
|
|
|
|
|
330-674-1363
|
|
www.NeedleZap.com
|
|
(Registrant’s telephone number)
|
|
(Registrant’s website)
|
Indicate by a check mark whether the
registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and
(2) has been subject to such filing requirements for the past 90 days. Yes
x
No
¨
Indicate by a check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.
|
|
|
|
|
Large Accelerated Filer
¨
|
|
Accelerated Filer
¨
|
|
Non-Accelerated Filer
¨
|
|
Smaller Reporting Company
x
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act). Yes
¨
No
x
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:
42,513,415 shares of common stock, $0.001 par value per share, as of November 14, 2008.
TABLE OF CONTENTS
PART I — FINANCIAL INFORMATION
|
Item 1.
|
Financial Statements
|
Our September 30, 2008 unaudited
consolidated financial statements follow this quarterly report beginning on page F-1.
|
Item 2.
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
Headquartered in Millersburg, Ohio, E Med Future, Inc. manufactures and markets products designed to reduce accidental hypodermic needlestick injuries. Our primary product, NeedleZap®, completely disintegrates the
sharp portion of the needle. According to the American Nursing Association, there are an estimated one million accidental needlesticks reported in the United States in the healthcare industry alone. We believe the applications for the product are
far reaching, and include healthcare professionals, law enforcement and correctional personnel, veterinarians, military, clinical researchers, hospitality, and sanitation workers. NeedleZap® is designed to work within the parameters of OSHA
needlestick mandates which require employers to take advantage of new technologies to prevent needlesticks in the workplace.
Our Products
Our primary product is the NeedleZap®, a revolutionary safety device intended to help reduce
accidental needlestick injuries by disintegrating the sharp portion of a hypodermic needle. When a hypodermic needle is inserted into the unit, the patented electrode system disintegrates the needle in approximately two seconds at 2200° F.
In July 2003, we announced the beginning of clinical testing and market evaluation of the first extensions to the NeedleZap® product line which
include a dental parking station and butterfly needle burner. We are presently in the process of obtaining patent protection for these new products. Because we lack sufficient funds to expedite the development of these products, both products remain
in the development phase. We anticipate that both products will involve supplements to our existing FDA pre-market approval; therefore, introduction and timing of these products into the marketplace will be contingent on FDA approval.
The dental parking station is intended to provide a safer, temporary resting place for a hypodermic syringe. During a procedure, dentists often reuse a hypodermic needle
on the same patient when additional anesthesia is required. Since the needle is not destroyed immediately after the initial use, dentists generally recap the needle or leave the needle exposed, increasing the risk of an accidental needlestick
injury. The NeedleZap® unit sits directly on the dental parking station enabling the dentist to recap, or disintegrate, the hypodermic needle easily with one hand at the end of the procedure, and significantly reducing the risk of a needlestick
injury.
The butterfly needle burner is intended to accommodate needles not secured to a hypodermic syringe. Butterfly needles are used primarily for
IV’s and kidney dialysis. Since the original
2
NeedleZap® unit was intended to disintegrate hypodermic needles held by a syringe, the butterfly needle burner necessitated design modifications,
including a change to the housing and repositioning of the electrode system.
On December 30, 2003, we acquired Medical Safety Technologies, Inc. from
UTEK Corporation (AMEX:UTK), an innovative technology transfer company dedicated to building bridges between university developed technologies and commercial organizations. Medical Safety Technologies, or MSTI, holds the worldwide exclusive license
to a patented invention, known as the “Safe Receptacle for Sharps,” that is designed to aid in the safe transport of sterile and used sharp medical instruments. This Emory University invention was developed to help reduce the possibility
of needlestick injuries by maintaining medical instruments in an angled, accessible position while encasing their sharp edges. We believe the Safe Receptacle for Sharps device is complementary to our NeedleZap® product. By expanding our future
product line, we hope to bring added value to the sales and distribution channel we are building. However, we are not presently pursuing the sharps receptacle as management believes resources should be conserved for marketing the currently approved
product.
Receivership
On
November 22, 2006, Martin Management Services, Inc. was appointed as receiver for E Med by the Franklin County, Ohio Common Pleas Court in the action filed on August 6, 2006 by Complete Investment Management, Ltd., or CIM, against the
Company. CIM has sought the repayment of a loan made by CIM to E Med in the amount of $548,000. E Med is in default in its payments to CIM due to declining revenue and cash flow. The receiver is currently operating the company for the benefit of its
creditors. The receiver has obtained offers to purchase the assets of E Med or to purchase a controlling interest of the shares of the company. The receiver is currently negotiating a potential sale and expects to have an agreement in place before
year-end. However, there can be no assurances that the receiver will be able to complete a transaction in that time frame or at all.
Looking Ahead
We incurred net losses while we obtained FDA approval and patent protection for our NeedleZap® product and entered into
distribution relationships. We have not had significant sales volume to date. We believe we have now obtained significant experience in how to market our products effectively and we had an increase in sales in 2007, which none the less were less
than projected. We cannot guarantee that sales will increase or that we will be able to attain profitability. We are currently in receivership and our future is uncertain.
Our History
The Company was formed under the laws of the State of Nevada on March 14,
1990, but until 2003 we were a shell company with no significant operations other than seeking to identify an existing business to acquire. Trading in our stock was dependant on our acquisition of an operating business. On April 4, 2003, we
participated in a merger in which we acquired E Med Future, Inc., our operating subsidiary. In connection with the transaction, we issued 19,850,000 unregistered shares of our common stock (95% of our then outstanding shares) to the former
stockholders of E Med Future.
3
Pursuant to the terms of the merger agreement, we changed our corporate name from “Micro-Economics, Inc.” to
“E Med Future, Inc.” In addition, our original directors resigned and were replaced by Robert J. Ochsendorf, D. Dane Donohue and Juan J. Perez. Our shares began trading on the OTC Bulletin Board under the symbol “EMDF.OB” on
April 17, 2003.
Results of Operations
We are a development stage company and did not have full approval to market and sell our products until March 2003. Initial sales in 2003 caused us to be optimistic that our revenues and profits would increase in
subsequent years. However, our results have not met expectations due to lower than anticipated sales. In 2007 we voluntarily suspended shipment of our products due to a Food and Drug Administration investigator that found deficiencies in or
operating procedures. We believe that we are now in compliance and resumed shipping product in the second quarter of 2008.
Third Quarter of 2008 Compared to 2007
Net Sales
We had sales of $23,031 in the quarter ended September 30, 2008, compared with only $120 for the same period in 2007, an increase of $22,911. In the third quarter of
2008, we completed one international sale. Due to our voluntary suspension of sales and shipments until we achieved FDA compliance, we had no sales in 2007 after July 15, hence the substantial third quarter increase in sales over the third
quarter of 2007.
Costs and Expenses
Operating costs and expenses decreased $11,851, or 19.0%, in the third quarter of 2008 to $49,177 from $61,028 in 2007. Operating costs and expenses for the third quarter of 2008 were lower due to the reduction of the Company’s
operations during 2008. Cost of goods sold was 28.5% and 319.2% for the third quarter of 2008 and 2007 respectively.
Other expenses increased $4,291, or
27.8%, to $19,746 in 2008 from $15,455 in 2007.
Net Loss
In the third quarter of 2008, our net loss decreased to $45,892 from a net loss of $76,363 in 2007 primarily as a result of increased sales and a reduction in staff.
First Nine Months of 2008 Compared to 2007
Net Sales
We had sales of $84,594 in the nine months ended September 30, 2008, compared with $123,268 for
the same period in 2007, a decrease of $38,674, or 31.4%. The reduction in sales for 2008 was caused by our voluntary suspension of sales and shipments during the first quarter while we achieved FDA compliance, partially offset by increased sales in
the second and third quarters.
Costs and Expenses
Operating costs and expenses decreased $60,060, or 24.1%, in the first nine months of 2008 to $189,507 from $249,567 in 2007. Operating costs and expenses for 2008 were lower due to a
4
reduction in staff and operating activities. Cost of goods sold as a percentage of sales was 45.9% in 2008 compared to 34.3% in 2007.
Other expenses increased $6,220, or 14.0%, to $50,667 in the first nine months of 2008 compared to $44,447 in 2007.
Net Loss
In the first nine months of 2008,
our net loss decreased to $155,570 from a net loss of $170,546 in 2007 primarily as a result of reduction in staff and operating activities.
Financial Condition and Liquidity
We had available cash of $25,843 on September 30, 2008, compared to $3,216 cash available at the end of
2007. During the second quarter of 2008, Ronald L. Alexander, one of our directors, loaned E Med $47,744. Available cash increased as a result of these loans partially offset by our lack of sales in the first quarter. We had cash used in operations
of $29,193 in the first nine months of 2008 compared to cash provided by operations of $28,521 in 2007.
On November 12, 2002, we entered into a
credit facility with Key Bank (NA). The facility provides us with a working capital line-of-credit of up to $150,000 and currently bears interest at 10.75%. The credit facility is secured by all of E Med’s assets and must be paid back in full
on demand. We presently have drawn $121,396 on the facility.
On April 1, 2004, we entered into
a loan agreement with a private investor in the amount of $750,000. The convertible promissory note bears interest at 7.5% payable quarterly with the principal due in five years and is secured by all of our assets. The note is convertible at the
holder’s option into 1.5 million shares of our unregistered common stock, subject to adjustment for dilutive issuances. In connection with the loan, we also agreed to pay the lender a $3.00 royalty on each of the first 1.0 million and
$2.00 on the second 1.0 million NeedleZap
®
units sold, with maximum total royalty payments of $5.0 million. The loan agreement was amended effective December 31, 2004 to reduce
the loan amount to $548,000. Payment of interest and royalties was deferred until January 1, 2006, provided we provide monthly sales reports to the lender when due. In addition, if we arrange an increase in bank financing, the lender agreed to
subordinate its security interests to the secured interests of the banking institution up to a maximum of $500,000. We have not paid royalties to the lender and are currently in default under the loan.
From September 2004 to June 2006, Mr. Alexander loaned E Med a total of $136,120. On June 15, 2006, we issued Mr. Alexander 3.5 million unregistered
shares in partial satisfaction of this loan. On June 28, 2006, a private investor purchased 1.5 million shares of our unregistered shares for $45,000, or $0.03 a share. On June 15, 2006, we issued 3.5 million unregistered shares
to Donald Sullivan, our CFO, interim CEO and a director, for payment of accrued wages from January 1, 2005 through May 31, 2006.
Our primary
need for capital is to fund operations and the development of new products. More recently we have been forced to expend significant funds to defend the company from various legal actions. Historically, our capital requirements have been met by a
combination of loans
5
from stockholders and other investors, our line of credit with Key Bank, and funds from operations. Although sales continue to be disappointing, we believe
increased sales may eventually meet our capital needs in the long-term. However, current sales are not adequate to meet our cash needs, and without additional loans or equity infusions we will not be able to continue our operations.
Off-Balance Sheet Arrangements
We do not
have any material off-balance sheet arrangements.
Forward Looking Statements
Some of the statements that we make in this report, including statements about our confidence in E Med’s prospects and strategies and our expectations about E
Med’s sales expansion, are forward-looking statements within the meaning of § 21E of the Securities Exchange Act. Some of these forward-looking statements can be identified by words like “believe,” “expect,”
“will,” “should,” “intend,” “plan,” or similar terms; others can be determined by context. Statements contained in this report that are not historical facts are forward-looking statements. These statements are
necessarily estimates reflecting our best judgment based upon current information, and involve a number of risks and uncertainties. Many factors could affect the accuracy of these forward-looking statements, causing our actual results to differ
significantly from those anticipated in these statements. While it is impossible to identify all applicable risks and uncertainties, they include:
|
•
|
|
our ability to continue operating as a going concern and emerge from receivership;
|
|
•
|
|
our ability to execute our business plan;
|
|
•
|
|
our ability to successfully market and sell our products;
|
|
•
|
|
our ability to continue to comply with rules and regulations governing our products;
|
|
•
|
|
our ability to gain and retain market share from our competitors, many of whom have greater financial and other resources than we do;
|
|
•
|
|
the introduction of competing products by other companies;
|
|
•
|
|
our ability to protect our patents, copyrights and other intellectual property rights;
|
|
•
|
|
pressure on pricing from our competitors or customers;
|
|
•
|
|
continued availability of components for our products and stability in the cost of these components;
|
|
•
|
|
our reliance on subcontractors to manufacture our products;
|
|
•
|
|
our reliance on independent distributors to market and sell our products;
|
|
•
|
|
our financial resources are limited and we are dependent on increasing sales to generate cash for operations; and
|
|
•
|
|
our ability to comply with SEC regulations and filing requirements applicable to us as a public company.
|
6
You should not place undue reliance on our forward-looking statements, which reflect our analysis only as of the date of
this report. The risks and uncertainties listed above and elsewhere in this report and other documents that we file with the Securities and Exchange Commission, including our annual report on Form 10-KSB, quarterly reports on Form 10-Q, and any
current reports on Form 8-K, must be carefully considered by any investor or potential investor in E Med.
How to Learn More
About E Med
We file annual, quarterly and special reports and other information with the SEC. Our SEC filings are available to the public over the
internet at the SEC’s web site at SEC.gov. You may also read and copy any document we file at the SEC’s public reference room at 450 Fifth Street, N.W., Washington, D.C. 20549. You may obtain information on the operation of the SEC’s
public reference room in Washington, D.C. by calling the SEC at 1-800-SEC-0330. To learn more about E Med you can also visit our website at NeedleZap.com or contact us directly at the address or phone number listed below.
E Med Future, Inc.
34 Clay Street
Millersburg, Ohio 44654
Phone: 330-674-1363
Email: info@NeedleZap.com
|
Item 4.
|
Controls and Procedures
|
Donald Sullivan, our chief financial
officer and interim president and chief executive officer, has evaluated the effectiveness of E Med’s disclosure controls and procedures as of September 30, 2008. Based upon his review, he concluded that our disclosure controls and
procedures are effective in ensuring that material information related to E Med is communicated to him by others within the company responsible for reporting this information. There were no changes in our internal controls over financial reporting
during the fiscal quarter ended September 30, 2008 that have materially affected, or are reasonably likely to affect, our internal controls over financial reporting.
PART II — OTHER INFORMATION
|
Item 1.
|
Legal Proceedings
|
On July 1, 2006, Kenneth Jackson filed a
petition for cancellation of the registration of the NeedleZap trademark (Registration Number 2620168) in the United States Patent and Trademark Office before the Trademark Trial and Appeal Board, or TTAB. The petition claimed that the trademark was
being used so as to misrepresent the source of goods or services on or in connection with which the mark is used. On January 31, 2008 Jackson agreed to dismiss the trademark cancellation petition. On July 15, 2008 Jackson filed a voluntary
dismissal with prejudice which was accepted and the proceeding dismissed July 23, 2008.
7
We are currently involved in several actions that we have disclosed in our previously filings with the SEC. For
additional information about these suits, please reference Item 3 of our December 31, 2007 Form 10-KSB that we filed with the SEC on April 22, 2008 and our 2006 10-KSB filed on April 17, 2007.
|
Item 2.
|
Unregistered Sales of Equity Securities and Use of Proceeds
|
Not
applicable.
|
Item 3.
|
Defaults Upon Senior Securities
|
Complete Investment Management
(“CIM”) has loaned E Med a total of $548,000. E Med is in default of its payment obligations and CIM has instituted suit in connection with this loan. We hope to arrive at a mutually agreeable settlement with CIM. In connection with this
suit, Martin Management Services, Inc. was appointed as receiver for the Company on November 22, 2006. Martin Management is currently operating E Med for the benefit of its creditors.
|
Item 4.
|
Submission of Matters to a Vote of Security Holders
|
Not
applicable.
|
Item 5.
|
Other Information
|
Not applicable.
|
|
|
|
|
31
|
|
Chief Financial Officer and Interim President and Chief Executive Officer’s Rule 13a-14(a)/15d-14(a) Certification Pursuant to § 302 of the Sarbanes-Oxley Act of
2002
|
|
|
|
|
32
|
|
Rule 13a-14(b)/15d-14(b) Certification Pursuant to § 906 of the Sarbanes-Oxley Act of 2002
|
8
SIGNATURES
In accordance with the requirements of the Exchange Act, E Med Future, Inc. caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
E M
ED
F
UTURE
, I
NC
.
|
|
|
|
|
|
Date: November 19, 2008
|
|
|
|
/s/ Donald Sullivan
|
|
|
|
By
|
|
Donald Sullivan, Chief Financial Officer and Interim Chief Executive Officer
|
9
E MED FUTURE, INC. AND SUBSIDIARY
(A Development Stage Company)
CONSOLIDATED BALANCE SHEETS
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30,
2008
|
|
|
December 31,
2007
|
|
|
|
(Unaudited)
|
|
|
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
|
CURRENT ASSETS
|
|
|
|
|
|
|
|
|
|
Cash
|
|
$
|
25,843
|
|
|
$
|
3,216
|
|
|
Inventory
|
|
|
72,393
|
|
|
|
61,574
|
|
|
Deposit
|
|
|
4,575
|
|
|
|
4,575
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Current Assets
|
|
|
102,811
|
|
|
|
69,365
|
|
|
|
|
|
|
EQUIPMENT, net of accumulated depreciation of $4,764 and $7,770, in 2008 and 2007, respectively
|
|
|
2,315
|
|
|
|
9,090
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL ASSETS
|
|
$
|
105,126
|
|
|
$
|
78,455
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ DEFICIT
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CURRENT LIABILITIES
|
|
|
|
|
|
|
|
|
|
Notes payable to bank
|
|
$
|
121,396
|
|
|
$
|
121,396
|
|
|
Current portion of note payable
|
|
|
—
|
|
|
|
1,089
|
|
|
Notes payable to related party
|
|
|
119,564
|
|
|
|
71,821
|
|
|
Accounts payable
|
|
|
399,485
|
|
|
|
318,851
|
|
|
Accounts payable to related party
|
|
|
41,369
|
|
|
|
41,369
|
|
|
Accrued expenses
|
|
|
445,927
|
|
|
|
390,974
|
|
|
Customer deposits
|
|
|
75,000
|
|
|
|
75,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,202,741
|
|
|
|
1,020,500
|
|
|
|
|
|
|
LONG-TERM DEBT
|
|
|
|
|
|
|
|
|
|
Convertible promissory note payable
|
|
|
548,000
|
|
|
|
548,000
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Long-Term Liabilities
|
|
|
548,000
|
|
|
|
548,000
|
|
|
|
|
|
|
STOCKHOLDERS’ DEFICIT
|
|
|
|
|
|
|
|
|
|
Common stock $0.001 par value, 50,000,000 authorized, 42,513,415 issued and outstanding at September 30, 2008 and December 31, 2007,
respectively
|
|
|
42,513
|
|
|
|
42,513
|
|
|
Paid-in-capital
|
|
|
3,476,637
|
|
|
|
3,476,637
|
|
|
Deficit accumulated during development stage
|
|
|
(5,164,765
|
)
|
|
|
(5,009,195
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Total Stockholders’ Deficit
|
|
|
(1,645,615
|
)
|
|
|
(1,490,045
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Total Liabilities and Stockholders’ Deficit
|
|
$
|
105,126
|
|
|
$
|
78,455
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to consolidated financial statements.
F-1
E MED FUTURE, INC. AND SUBSIDIARY
(A Development Stage Company)
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
September 30,
|
|
|
Nine Months Ended
September 30,
|
|
|
Period
March 14, 1990
(Inception) to
September 30,
2008
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
|
NET SALES
|
|
$
|
23,031
|
|
|
$
|
120
|
|
|
$
|
84,594
|
|
|
$
|
123,268
|
|
|
$
|
1,210,873
|
|
|
|
|
|
|
|
|
|
COSTS AND EXPENSES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of goods sold
|
|
|
6,499
|
|
|
|
383
|
|
|
|
38,820
|
|
|
|
42,223
|
|
|
|
1,084,531
|
|
|
Selling, general and administrative
|
|
|
42,376
|
|
|
|
60,098
|
|
|
|
149,292
|
|
|
|
205,819
|
|
|
|
2,305,739
|
|
|
Impairment of long lived assets
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
273,844
|
|
|
Research and development
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
16,747
|
|
|
Consulting expense
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
2,112,400
|
|
|
Impairment of goodwill
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
188,500
|
|
|
Depreciation and amortization
|
|
|
302
|
|
|
|
547
|
|
|
|
1,395
|
|
|
|
1,525
|
|
|
|
149,462
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Costs and Expenses
|
|
|
49,177
|
|
|
|
61,028
|
|
|
|
189,507
|
|
|
|
249,567
|
|
|
|
6,131,223
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NET OPERATING LOSS
|
|
|
(26,146
|
)
|
|
|
(60,908
|
)
|
|
|
(104,913
|
)
|
|
|
(126,299
|
)
|
|
|
(4,920,350
|
)
|
|
|
|
|
|
|
|
|
OTHER INCOME (EXPENSE)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss On Disposal of Fixed Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss on disposal of fixed assets
|
|
|
(4,291
|
)
|
|
|
—
|
|
|
|
(4,291
|
)
|
|
|
—
|
|
|
|
(4,291
|
)
|
|
Interest and other income
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
5,865
|
|
|
Interest expense
|
|
|
(15,455
|
)
|
|
|
(15,455
|
)
|
|
|
(46,366
|
)
|
|
|
(44,447
|
)
|
|
|
(245,989
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Other Income (Expense)
|
|
|
(19,746
|
)
|
|
|
(15,455
|
)
|
|
|
(50,657
|
)
|
|
|
(44,447
|
)
|
|
|
(244,415
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NET LOSS
|
|
$
|
(45,892
|
)
|
|
$
|
(76,363
|
)
|
|
|
(155,570
|
)
|
|
$
|
(170,746
|
)
|
|
|
(5,164,765
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NET LOSS PER COMMON SHARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Basic and diluted)
|
|
$
|
(0.00
|
)
|
|
$
|
(0.00
|
)
|
|
$
|
(0.00
|
)
|
|
$
|
(0.00
|
)
|
|
$
|
(0.45
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
WEIGHTED AVERAGE SHARES OUTSTANDING
|
|
|
42,513,415
|
|
|
|
42,513,415
|
|
|
|
42,513,415
|
|
|
|
42,513,415
|
|
|
|
11,472,989
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to consolidated financial statements.
F-2
E MED FUTURE, INC. AND SUBSIDIARY
(A Development Stage Company)
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30,
|
|
|
Period March 14,
1990 (Inception)
to September 30,
2008
|
|
|
|
|
2008
|
|
|
2007
|
|
|
|
CASH FLOWS FROM OPERATING ACTIVITIES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(155,580
|
)
|
|
$
|
(170,746
|
)
|
|
$
|
(5,146,765
|
)
|
|
Adjustments to reconcile net loss to net cash flows from operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
1,395
|
|
|
|
1,525
|
|
|
|
149,462
|
|
|
Consulting expense
|
|
|
—
|
|
|
|
—
|
|
|
|
2,112,400
|
|
|
Research and development
|
|
|
—
|
|
|
|
—
|
|
|
|
8,808
|
|
|
Start-up costs
|
|
|
—
|
|
|
|
—
|
|
|
|
19,177
|
|
|
Amortization of prepaid expenses
|
|
|
—
|
|
|
|
—
|
|
|
|
39,913
|
|
|
Loss on inventory obsolescence
|
|
|
—
|
|
|
|
—
|
|
|
|
225,110
|
|
|
Impairment of long lived assets
|
|
|
—
|
|
|
|
—
|
|
|
|
273,844
|
|
|
Impairment of goodwill
|
|
|
—
|
|
|
|
—
|
|
|
|
188,500
|
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
—
|
|
|
|
358
|
|
|
|
—
|
|
|
Inventory
|
|
|
(10,819
|
)
|
|
|
21,137
|
|
|
|
(146,488
|
)
|
|
Prepaid expenses
|
|
|
—
|
|
|
|
—
|
|
|
|
(9,312
|
)
|
|
Deposits
|
|
|
—
|
|
|
|
—
|
|
|
|
(4,575
|
)
|
|
Accounts payable
|
|
|
80,634
|
|
|
|
63,949
|
|
|
|
413,622
|
|
|
Accounts payable to related party
|
|
|
—
|
|
|
|
—
|
|
|
|
39,216
|
|
|
Accrued expenses
|
|
|
55,177
|
|
|
|
112,298
|
|
|
|
516,151
|
|
|
Customer deposits
|
|
|
—
|
|
|
|
—
|
|
|
|
75,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) operating activities
|
|
|
(29,193
|
)
|
|
|
28,521
|
|
|
|
(1,263,937
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM INVESTING ACTIVITIES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchases of property and equipment
|
|
|
—
|
|
|
|
—
|
|
|
|
(94,806
|
)
|
|
Disposal of property and equipment
|
|
|
5,166
|
|
|
|
—
|
|
|
|
5,166
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in investing activities
|
|
|
5,166
|
|
|
|
—
|
|
|
|
(89,640
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM FINANCING ACTIVITIES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of common stock
|
|
|
—
|
|
|
|
—
|
|
|
|
45,000
|
|
|
Initial capitalization
|
|
|
—
|
|
|
|
—
|
|
|
|
1,666
|
|
|
Cash acquired in acquisition
|
|
|
—
|
|
|
|
—
|
|
|
|
200,000
|
|
|
Notes payable
|
|
|
(1,089
|
)
|
|
|
(27,702
|
)
|
|
|
121,396
|
|
|
Convertible promissory notes payable
|
|
|
—
|
|
|
|
—
|
|
|
|
548,000
|
|
|
Notes payable to related party
|
|
|
47,743
|
|
|
|
3,201
|
|
|
|
463,358
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by financing activities
|
|
|
46,654
|
|
|
|
(24,501
|
)
|
|
|
1,379,420
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NET INCREASE IN CASH
|
|
|
22,627
|
|
|
|
4,020
|
|
|
|
25,843
|
|
|
CASH, BEGINNING OF PERIOD
|
|
|
3,216
|
|
|
|
8,947
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH, END OF PERIOD
|
|
$
|
25,843
|
|
|
$
|
12,967
|
|
|
$
|
25,843
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to consolidated financial statements.
F-3
E MED FUTURE, INC. AND SUBSIDIARY
(A Development Stage Company)
CONSOLIDATED STATEMENTS OF CASH FLOWS
(CONTINUED) (UNAUDITED)
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended
September 30,
|
|
Period March 14,
1990 (Inception)
to September 30,
2008
|
|
|
|
2008
|
|
2007
|
|
|
Supplemental Disclosure of Cash Flow Information:
|
|
|
|
|
|
|
|
|
|
Interest paid
|
|
—
|
|
$
|
7,298
|
|
$
|
46,207
|
|
Supplemental Schedule of Non-Cash Investing and Financing Activities:
|
|
|
|
|
|
|
|
|
|
Needlezap Partnership Contribution of Assets to Company
|
|
|
|
|
|
|
|
|
|
Inventory
|
|
—
|
|
|
—
|
|
|
151,015
|
|
Equipment
|
|
—
|
|
|
—
|
|
|
133,912
|
|
Patent
|
|
—
|
|
|
—
|
|
|
189,089
|
|
Issuance of 1,500,000 shares valued at $0.03 to acquire Trademark
|
|
—
|
|
|
—
|
|
|
45,000
|
|
Issuance of common stock for consulting services and compensation
|
|
—
|
|
|
—
|
|
|
2,259,067
|
|
Loss on inventory obsolescence
|
|
—
|
|
|
—
|
|
|
225,110
|
|
Impairment of long lived assets
|
|
—
|
|
|
—
|
|
|
273,844
|
|
Issuance of 1,250,000 shares valued at $0.3108 per share to acquire MSTI and allocation of purchase price to license
|
|
—
|
|
|
—
|
|
|
188,500
|
|
Issuance of common stock in payment of loan
|
|
—
|
|
|
—
|
|
|
336,484
|
|
Issuance of common stock in payment of accounts payable
|
|
—
|
|
|
—
|
|
|
12,000
|
|
Issuance of common stock in payment of accrued wages
|
|
—
|
|
|
—
|
|
|
70,000
|
|
Settlement of accounts payable with fixed assets
|
|
—
|
|
|
—
|
|
|
7,310
|
See accompanying notes to consolidated financial statements.
F-4
E MED FUTURE, INC. AND SUBSIDIARY
(A Development Stage Company)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
September 30, 2008
(Unaudited)
NOTE A - BASIS OF PRESENTATION
The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim
financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal
recurring accruals) considered necessary in order to make the financial statements not misleading have been included. Results for the three and nine months ended September 30, 2008 are not necessarily indicative of the results that may be
expected for the year ending December 31, 2008. For further information, refer to the financial statements and footnotes thereto included in the E Med Future, Inc. annual report on Form 10-KSB for the year ended December 31, 2007.
NOTE B - GOING CONCERN
As indicated in the
accompanying financial statements, the Company incurred a net loss of $155,570 for the nine months ended September 30, 2008, and has a negative working capital of $1,099,930 and an Accumulated Deficit of $5,164,765 at September 30, 2008,
and is considered a company in the development stage. Management’s plans include the raising of capital through short term financing to fund future operations and the generating of revenue through its business. Failure to raise capital, keep
its products and manufacturing facilities in FDA compliance, and generate sales revenues could result in the Company having to curtail or cease operations. Additionally, even if the Company does raise sufficient capital to support its operating
expenses and generate revenues, there can be no assurances that the revenue will be sufficient to enable it to develop business to a level where it will generate profits and cash flows from operations. These matters raise substantial doubt about the
Company’s ability to continue as a going concern. However, the accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of
business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.
NOTE C - CONCENTRATION
Approximately 90% of
the Company’s sales for the nine months ended September 30, 2008 were with two customers.
NOTE D - CONVERTIBLE PROMISSORY NOTE PAYABLE
On November 22, 2006, Martin Management Services, Inc. was appointed as receiver for E Med by the Franklin County, Ohio Common Pleas
Court in the action filed on August 6, 2006 by Complete Investment Management, Ltd., or CIM, against the Company. CIM has sought the repayment of a loan made by CIM to E Med in the amount of $548,000. E Med is in default in its payments to CIM
due to declining revenue and cash flow. The receiver is currently operating the company for the benefit of its creditors. The receiver has obtained offers to purchase the assets of E Med or to purchase a controlling interest of the shares of the
company. The receiver is currently negotiating a potential sale and expects to have an agreement in place before year-end. However, there can be no assurances that the receiver will be able to complete a transaction in that time frame or at all.
NOTE F - COMMITMENTS AND CONTINGENCIES
From
July 9 through July 25, 2007, a Food and Drug Administration investigator conducted an inspection of the Company’s operations. At the conclusion of the inspection an FDA Form 483 was issued to the company listing observations of the
inspector, which the Company responded to on August 7, 2007. The observations included deficiencies in the Company’s operating procedures, which required correction. The Company voluntarily suspended shipment of our products to assure that
the Company is compliant. The Company has completed the corrections and requested a re-inspection by the FDA. The Company has received verbal approval from the FDA
F-5
E MED FUTURE, INC. AND SUBSIDIARY
(A Development Stage Company)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENT
September 30, 2008
(Unaudited)
NOTE F - COMMITMENTS AND CONTINGENCIES (Continued)
to resume shipments if the Company believes it is in compliance. The Company believes it is now in compliance.
On or about January 20, 2008, the Receiver entered into a settlement agreement with Kenneth Jackson and Safe Medical Solutions, LLC, which was filed
of record in
Complete Investment Management, Inc. v. E Med Future, Inc.
, Case No. 06 CVH 10019 (Franklin County, Ohio Court of Common Pleas, J. Frye) on January 25, 2008. On January 31, 2008, an Agreed Order for Permanent
Injunctive Relief was filed in the same case. Pursuant to the agreement, the parties agree to dismiss and release all claims within
Safe Medical Solutions, LLC v. Sullivan, et al.
, Case No. 06 CV 9757 (Franklin County Court of Common
Pleas, J. Brown). Jackson and Safe Medical agree to dismiss the Cancellation Action No. 92045999, pending before the U.S. Trademark Trial Appeal Board, with regard to the Needlezap trademark. The Receiver agrees to release all cross-claims as
against Jackson and Safe Medical in the
Safe Medical
case. Jackson and Safe Medical surrender and waive any claim of ownership or license with regard to any intellectual property, including trademarks and patents, related to the Needlezap
product, but retain the right to receive royalties on the future sale of Needlezap units. Jackson and Safe Medical also retain the right to sell any Needlezap units they currently own. The Receiver agreed with Jackson to either contract for the sale
of, or offer up for public sale, all assets of E Med within 120 days of the agreement. Jackson and Safe Medical retain a limited “right of first refusal” with regard to any sale of the E Med assets. While IMET Corporation remains a
third-party defendant in the
Complete Investment
case, the Receiver anticipates that all claims will shortly be resolved and IMET dismissed from the action.
F-6
Grafico Azioni E Med Future (PK) (USOTC:EMDF)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni E Med Future (PK) (USOTC:EMDF)
Storico
Da Giu 2023 a Giu 2024
